S&P Futures
4,007.75 +0.50 (+0.01%) Dow Futures
32,670.00 +39.00 (+0.12%) Nasdaq Futures
12,773.75 -14.75 (-0.12%) Russell 2000 Futures
1,767.60 +0.30 (+0.02%) Crude Oil
73.21 +0.40 (+0.55%) Gold
1,952.70 -1.10 (-0.06%)
Rocket Pharmaceuticals Inc (9IP1.MU)
Chart Events
Performance Outlook
| Previous Close | 15.82 |
| Open | 15.69 |
| Bid | 15.16 x N/A |
| Ask | 15.62 x N/A |
| Day's Range | 15.69 - 15.69 |
| 52 Week Range | 7.68 - 21.02 |
| Volume | |
| Avg. Volume | 6 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 9IP1.MU
Related Research
- Business Wire
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
CRANBURY, N.J., March 01, 2023--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in the Genetic Medicines Corporate Panel at the 43rd Annual Cowen Health Care Conference taking place in Boston, MA on Monday, March 6, 2023 at 10:30 a.m. ET.
- Insider Monkey
What Makes Rocket Pharmaceuticals (RCKT) Shares Attractive?
Baron Funds, an investment management company, released its “Baron Opportunity Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund declined 4.54% (Institutional Shares) compared to a 2.31% return for the Russell 3000 Growth Index and a 7.56% return for the S&P 500 Index. For […]
- Business Wire
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
CRANBURY, N.J., February 27, 2023--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2022.
